Search results
Results From The WOW.Com Content Network
However, the rising dividend yield seems to be just a byproduct of the market selling Pfizer stock off for its declining sales. Management even raised guidance in Q1. Management even raised ...
In contrast to AbbVie, Pfizer (NYSE: PFE) stands out as more of a turnaround opportunity, offering investors the chance to pick up shares in a pharmaceutical industry leader at a discount, down ...
The good news on this front, though, is that Pfizer is poised to improve its bottom line and make its dividend even safer. Sure, the big pharma company's earnings fell 11% year over year in Q2.
A high-yield dividend stock with long-term potential Pfizer's current 5.73% dividend yield stands well above the S&P 500 average of 1.35%. The company's payout ratio of 443% appears unsustainable ...
The S&P 500 Dividend Aristocrats is a stock market index composed of the companies in the S&P 500 index that have increased their dividends in each of the past 25 consecutive years. It was launched in May 2005.
Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% dividend yield -- the highest among major drug manufacturers and one of the ...
With a lot of new drugs to sell, Pfizer expects adjusted earnings to reach a range between $2.15 and $2.35 per share this year, which is more than it needs to meet a dividend commitment currently ...
For premium support please call: 800-290-4726 more ways to reach us